Is Aurinia Pharmaceuticals' Management Its Best Asset?
Richard Glickman was the founder and CEO of Aspreva Pharmaceuticals, a small company that he sold for $915 million in 2008 after it developed CellCept, a treatment that today is commonly used in lupus nephritis (LN) patients.
Nowadays, Glickman's at it again as the founder and CEO of Aurinia Pharmaceuticals (NASDAQ: AUPH), a company that's developing voclosporin, a drug that can be used alongside CellCept in the same disease. Can Glickman reshape this indication a second time?
Source: Fool.com
Aurinia Pharmaceuticals Inc. Aktie
5,18 €
1,65 %
Wenige Einschätzungen bei Aurinia Pharmaceuticals Inc. lassen noch kein klares Bild zu.
Dadurch ergibt sich bei einem Kursziel von 8 € ein stark positives Potenzial von 54.5% im Vergleich zum aktuellen Kurs von 5.18 € bei Aurinia Pharmaceuticals Inc..
